3-V Biosciences Names Dr. William McCulloch Chief Medical Officer

      3-V Biosciences Names Dr. William McCulloch Chief Medical Officer

PR Newswire

MENLO PARK, Calif., Nov. 21, 2013

MENLO PARK, Calif., Nov. 21, 2013 /PRNewswire/ --3-V Biosciences, Inc. (3-V),
a clinical-stage biopharmaceutical company developing therapeutics that
modulate key pathways in oncology and infectious disease, today announced that
William McCulloch, MB, ChB, FRCP, FFPM has joined the company as Chief Medical
Officer. Dr. McCulloch brings nearly three decades of senior research and
development experience to 3-V, including an extensive preclinical and clinical
development background in oncology. Dr. McCulloch will be responsible for
3-V's clinical, medical affairs and regulatory functions, overseeing strategy
and implementation for the advancement of 3-V's pipeline of proprietary
therapeutic candidates.

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO)

"With a thorough understanding of the oncology field and many years of
relevant experience in the pharmaceutical and biotech industries, Bill brings
significant breadth and depth to our executive team," said Merdad Parsey,
M.D., Ph.D., Chief Executive Officer of 3-V Biosciences. "Bill will provide
invaluable leadership as we move forward in the clinical evaluation of our
lead FASN inhibitor in patients with solid tumors."

"I look forward to leading the development of TVB-2640, a promising fatty acid
synthase inhibitor, through clinical development. Our first study will explore
safety, dosing levels and initial anti-cancer activity in patients with
advanced solid tumors," said Dr. McCulloch. "I was attracted to this position
based on the potential of TVB-2640, as well as 3-V's wealth of opportunity
based on its drug discovery capabilities, leadership team and backing from top
venture capital firms."

Dr. McCulloch previously served as Chief Medical Officer at Gloucester
Pharmaceuticals, Inc., where he led the regulatory strategy and oversaw the
conduct of the pivotal trial that led to approval by the U.S. Food and Drug
Administration of their HDAC inhibitor romidepsin (Istodax^®) in November 2009
and the subsequent acquisition of Gloucester by Celgene Corporation in January
2010. He also served as an Executive Vice President and Medical Director at
Pappas Ventures, lending his clinical and medical expertise to their portfolio
companies. Dr. McCulloch has worked for large pharmaceutical companies
Bristol-Myers and Astra AB, start-up companies U.S. Bioscience and Sparta
Pharmaceuticals, and most recently has served as President of Alba BioPharm
Advisors, Inc. He has undertaken all phases of drug and technology
development and has been directly involved in the U.S. and Europe in filing
INDs/CTAs and NDAs/MAAs, with their requisite face-to-face regulatory
meetings, securing orphan drug status for compounds and obtaining SBIR and
other grant funding for his projects. Dr. McCulloch practiced medicine for
seven years in the U.K., including post-graduate training in Internal
Medicine, Hematology and Oncology, before joining the international
pharmaceutical industry in 1984. He holds a medical degree (M.B., Ch.B.) from
the University of Glasgow in Scotland, is a Fellow of the Royal College of
Physicians of Glasgow and is also a Fellow of the Faculty of Pharmaceutical
Medicine of the Royal Colleges of Physicians of the United Kingdom.

About FASN Inhibition
FASN over-expression is associated with aggressive disease and poor prognosis
in a number of cancers. In a series of preclinical studies, 3-V's FASN
inhibitors demonstrated potent activity against multiple tumor types,
including breast, lung, pancreatic, ovarian and colon cancers. Single-agent
and combinations of 3-V FASN inhibitors have both blocked tumor growth and
resulted in significant tumor regression in patient-derived xenografts.

About 3-V Biosciences
3-V Biosciences, Inc. is a privately held biopharmaceutical company
discovering and developing therapeutics that modulate key pathways in oncology
and infectious disease. In oncology, the company's lead candidate is a fatty
acid synthase (FASN) inhibitor that blocks tumor cell signaling pathways and
induces tumor cell apoptosis. 3-V's antiviral therapeutics block
host-pathogen interactions, resulting in robust and broad-spectrum antiviral
activity, including efficacy against viruses resistant to other classes of
antiviral drugs, and a high barrier to resistance. The 3-V team applies an
integrated approach, leveraging internal expertise in biology, medicinal
chemistry, drug discovery and development to drive programs forward. The
company is located in Menlo Park, California.

For additional information on 3-V Biosciences, please visit www.3vbio.com.

Contact Information
Merdad Parsey, M.D., Ph.D.
Chief Executive Officer
650-561-8600

Media Inquiries
BCC Partners on behalf of 3-V Biosciences, Inc.
Karen L. Bergman
650-575-1509
kbergman@bccpartners.com
Michelle Corral
415-794-8662
mcorral@bccpartners.com

SOURCE 3-V Biosciences, Inc.

Website: http://www.3vbio.com
 
Press spacebar to pause and continue. Press esc to stop.